Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
UPMC Shadyside Radiation Oncology
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
UPMC Shadyside Radiation Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
UPMC Presbyterian/Montifore
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
UPMC Presbyterian/Montifore
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety Study of Modified Vaccinia Virus to Cancer
A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection
Status: Enrolling
Updated:  12/23/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Safety Study of Modified Vaccinia Virus to Cancer
A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection
Status: Enrolling
Updated: 12/23/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Status: Enrolling
Updated:  12/23/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Status: Enrolling
Updated: 12/23/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
City of Hope National Medical Center
mi
from
Duarte, CA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Swedish Cancer Institute
mi
from
Seattle, WA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
The Jones Clinic, PC
mi
from
Germantown, TN
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
University of Louisville/James Graham Brown Cancer Center
mi
from
Louisville, KY
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
University of Louisville/James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
UW Carbone Cancer Center
mi
from
Madison, WI
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
UW Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
University of British Columbia and Vancouver General Hospital
mi
from
Vancouver,
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
University of British Columbia and Vancouver General Hospital
mi
from
Vancouver,
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/6/2016
Moores UCSD Cancer Center
mi
from
La Jolla, CA
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/6/2016
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/6/2016
The Mayo Clinic
mi
from
Rochester, MN
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/6/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/6/2016
Billings Clinic Cancer Center
mi
from
Billings, MT
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/6/2016
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/6/2016
Ohio State University
mi
from
Columbus, OH
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/6/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/6/2016
University of Pittsburgh Medical Center - Liver Cancer Center
mi
from
Pittsburgh, PA
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/6/2016
University of Pittsburgh Medical Center - Liver Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/6/2016
McMaster University Medical Centre
mi
from
Hamilton,
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/6/2016
McMaster University Medical Centre
mi
from
Hamilton,
Click here to add this to my saved trials
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)
Status: Enrolling
Updated:  1/8/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)
Status: Enrolling
Updated: 1/8/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Helen F. Graham Cancer Center
mi
from
Newark, DE
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated:  1/14/2016
Methodist Cancer Center
mi
from
Omaha, NE
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101
Status: Enrolling
Updated: 1/14/2016
Methodist Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated:  1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Enrolling
Updated: 1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/15/2016
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/15/2016
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma
Phase II Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres As First-Line Treatment For Cholangiocarcinoma
Status: Enrolling
Updated:  1/19/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma
Phase II Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres As First-Line Treatment For Cholangiocarcinoma
Status: Enrolling
Updated: 1/19/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/19/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/19/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/19/2016
Mayo Clinic
mi
from
Scottsdale, AZ
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/19/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  1/19/2016
Pusan National University Hospital
mi
from
Pusan,
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 1/19/2016
Pusan National University Hospital
mi
from
Pusan,
Click here to add this to my saved trials